| Original language | English |
|---|---|
| Pages (from-to) | 388-390 |
| Number of pages | 3 |
| Journal | The Lancet Gastroenterology and Hepatology |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Gastroenterology and Hepatology, Vol. 7, No. 5, 05.2022, p. 388-390.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Global multi-stakeholder endorsement of the MAFLD definition
AU - Global multi-stakeholder consensus on the redefinition of fatty liver disease
AU - Méndez-Sánchez, Nahum
AU - Bugianesi, Elisabetta
AU - Gish, Robert G.
AU - Lammert, Frank
AU - Tilg, Herbert
AU - Nguyen, Mindie H.
AU - Sarin, Shiv K.
AU - Fabrellas, Núria
AU - Zelber-Sagi, Shira
AU - Fan, Jian Gao
AU - Shiha, Gamal
AU - Targher, Giovanni
AU - Zheng, Ming Hua
AU - Chan, Wah Kheong
AU - Vinker, Shlomo
AU - Kawaguchi, Takumi
AU - Castera, Laurent
AU - Yilmaz, Yusuf
AU - Korenjak, Marko
AU - Spearman, C. Wendy
AU - Ungan, Mehmet
AU - Palmer, Melissa
AU - El-Shabrawi, Mortada
AU - Gruss, Hans Juergen
AU - Dufour, Jean François
AU - Dhawan, Anil
AU - Wedemeyer, Heiner
AU - George, Jacob
AU - Valenti, Luca
AU - Fouad, Yasser
AU - Romero‐Gomez, Manuel
AU - Eslam, Mohammed
AU - Abate, Maria Lorena
AU - Abbas, Bahaa
AU - Abbassy, Ahmed Amr
AU - Abd El Ghany, Waleed
AU - Abd Elkhalek, Amira
AU - Abd ElMajeed, Emad
AU - Abdalgaber, Mohammad
AU - AbdAllah, Mohamed
AU - Abdallah, Marwa
AU - Abdallah, Nourhan
AU - Abdelaleem, Shereen
AU - Abdelghani, Yasser
AU - Abdelghany, Wael
AU - Abdelhalim, Safaa Mohamed
AU - Abdelhamid, Wafaa
AU - Abdelhamid, Nehal
AU - Hamid, Saeed
AU - Jafri, Wasim
N1 - Funding Information: HW reports personal fees from Falk Foundation, Gore, Intercept, Pfizer, Merz, and Norgine; and grants from Merz and from Norgine, unrelated to this Correspondence. W-KC reports personal fees from Abbvie, Novo Nordisk, Boehringer Ingelheim, Viatris, and Hisky Medical, unrelated to this Correspondence. TK reports honorarium for lectures from Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical, and EA Pharma, unrelated to this Correspondence. LC reports personal fees from Alexion, AbbVie, Echosens, Gilead, Intercept, Merck, Novo Nordisk, and Pfizer; and grants from Gilead, unrelated to this Correspondence. MHN reports grants from Glycotest, Gilead, Pfizer, Enanta, BK Kee Foundation, National Cancer Institute, and Vir Biotech; and personal fees from Spring Bank, Novartis, Janssen Eisai, Bayer, Intercept, Exact Science, Laboratory of Advanced Medicine, Helio, and Eli Lilly. MHN also reports acting as a consultant or on an advisory board for Gilead, unrelated to this Correspondence. LV reports grants from Gilead and personal fees from Viatris, unrelated to this Correspondence. RGG has received grants or research support in past 2 years from Gilead. RGG has also performed as a consultant or advisor in the past 2 years to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. RGG has performed as a consultant, advisor, or both to Topography Health. RGG is chair of the clinical advisory board for Prodigy. RGG is an advisory consultant for Fibronostics, Fujifilm–Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect. RGG currently has consulting confidentiality agreements with AbbVie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals, ArrowHead, Arterys, Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Association, CymaBay Therapeutics, DiaSorin, Dova Pharmaceuticals, DRG Abacus, Durect, Dynavax, Echosens, Eiger, Enyp, Exelixis, Fibronostics, Forty-Seven, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen–Johnson & Johnson, KannaLife, Laboratory for Advanced Medicine, Labyrinth, Life Line Screening, Eli Lilly, MedImmne, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Prodigy Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi, Spring Bank, and Trimaran. RGG has speaker's contracts to do promotional talks for AbbVie, Bristol Myers Squibb, Eisai, Gilead Sciences, and Intercept. RGG is a minor stock shareholder (only for projects in the liver field but not fatty liver disease-related areas) for RiboSciences and CoCrystal. RGG holds stock options in Eiger, Genlantis, HepQuant, and AngioCrine, unrelated to this Correspondence. All other authors declare no competing interests.
PY - 2022/5
Y1 - 2022/5
UR - http://www.scopus.com/inward/record.url?scp=85127533180&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(22)00062-0
DO - 10.1016/S2468-1253(22)00062-0
M3 - Letter
C2 - 35248211
AN - SCOPUS:85127533180
SN - 2468-1253
VL - 7
SP - 388
EP - 390
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 5
ER -